Clinical efficacy of clonazepam in the treatment of status epilepticus.

To explore the clinical efficacy of clonazepam in the treatment of status epilepticus. Totally 60 patients with status epilepticus were identified as research subjects and assigned (1:1) via the randomized double-blind method to receive either diazepam (Valium) comparison group) or clonazepam (observation group). After treatment and follow-up visits, the treatment efficacy, incidence of adverse reactions, quality of life, and recurrence were evaluated and compared between the two groups. The total effective rate of the observation group was 93.33%, which was higher than that of 66.67% in the comparison group (P<0.05). A longer mean duration of drug effect was observed in the observation group than in the comparison group (P<0.05). The observation group outperformed the comparison group in terms of quality of life (P<0.05). The observation group had a lower incidence of adverse reactions than the comparison group (P<0.05). The overall recurrence rate in the comparison group was 23.33%, which was significantly higher than that of 6.67% in the observation group (P<0.05). Clonazepam yields a promising efficacy in the treatment of patients with status epilepticus.